Edgar Filing: CORTEX PHARMACEUTICALS INC/DE/ - Form 144

CORTEX PHARMACEUTICALS INC/DE/ Form 144 May 18, 2011

> OMB APPROVAL OMB Number: 3235-0101 Expires: February 28, 2014 Estimated average burden hours per response ...1.00 SEC USE ONLY DOCUMENT SEQUENCE NO.

CUSIP NUMBER

WORK LOCATION

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 144

NOTICE OF PROPOSED SALE OF SECURITIES

PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

ATTENTION: Transmit for filing 3 copies of this form concurrently with either placing an order with a broker to execute sale or executing a sale directly with a market maker.

1(a) NAME OF ISSUER (Please type or print)

(b) IRS IDENT. NO.

330303583

(c) S.E.C. FILE NO.

Cortex Pharmaceuticals, Inc. 1(d) ADDRESS OF ISSUER

STREET

CITY

STATE

ZIP CODE

001-16467

California

(e) TELEPHONE NO. AREA CODE NUMBER

15241 Barranca Parkway

Irvine

92618

949

727-3157

2(a) NAME OF PERSON FOR WHOSE ACCOUNT THE SECURITIES ARE TO BE SOLD

(b) RELATIONSHIP TO (c) ADDRESS **ISSUER**

STREET

CITY

STATE ZIP CODE

Samyang Optics Co., Ltd.

10% Shareholder

654-4 Bongamdong, Masanhoiwongu, Changwonsi,

INSTRUCTION: The person filing this notice should contact the issuer to obtain the I.R.S. Identification Number and the S.E.C. File Number.

Edgar Filing: CORTEX PHARMACEUTICALS INC/DE/ - Form 144

		SEC			(e)	(f)	
3(a)	(b) Name and Address of Each Broker	USE ONLY		(d)	J Cl		(g)
Title of the	Name and Address of Each Broker	Broker-Deale	rumber of Shar	esaggregate	Number of Share	es Approximate	Name of Each
Class of	Through Whom the Securities are	File Number	or Other Units	Market Value	or Other Units	Date of Sale	Securities
Securities	to be Offered or Each Market				Outstanding	(See instr. $3(f)$)	Exchange
			To Be Sold (See instr. 3(d))				
To Be Sold	Maker who is Acquiring				(See instr.	(MO. DAY YR.)	(See instr. 3(g))
			(See instr.		<i>3(e))</i>		
	the Securities		<i>3(c))</i>				
Common Stock	Hanmi Asset Securities, Inc. 3600 Wilshire Blvd. Suite 2226 Los Angeles, CA 90010		788,581	\$94,629 (1)	78,858,197 (2)	05/18/2011 TO 08/17/2011 (3months)	ОТСВВ

INSTRUCTIONS:

- 1. (a) Name of issuer
 - (b) Issuer s I.R.S. Identification Number
 - (c) Issuer s S.E.C. file number, if any
 - (d) Issuer s address, including zip code
 - (e) Issuer s telephone number, including area code
- 2. (a) Name of person for whose account the securities are to be sold
 - (b) Such person s relationship to the issuer (e.g., officer, director, 10% stockholder, or member of immediate family of any of the foregoing)
 - (c) Such person s address, including zip code
- 3. (a) Title of the class of securities to be sold
 - (b) Name and address of each broker through whom the securities are intended to be sold
 - (c) Number of shares or other units to be sold (if debt securities, give the aggregate face amount)
 - (d) Aggregate market value of the securities to be sold as of a specified date within 10 days prior to the filing of this notice
 - (e) Number of shares or other units of the class outstanding, or if debt securities the face amount thereof outstanding, as shown by the most recent report or statement published by the issuer
 - (f) Approximate date on which the securities are to be sold
 - (g) Name of each securities exchange, if any, on which the securities are intended to be sold

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1147 (08-07)

TABLE I SECURITIES TO BE SOLD

Furnish the following information with respect to the acquisition of the securities to be sold

and with respect to the payment of all or any part of the purchase price or other consideration therefor:

Title of	Date you		Name of Person from Whom Acquired		Date of	
the Class	Acquired	Nature of Acquisition Transaction	(If gift, also give date donor acquired)	Amount of Securities Acquired	Payment	Nature of Payment
Common	06/07/2010	Conversion from a convertible promissory note	Cortex Pharmaceuticals, Inc.	14,527,212	01/15/2010	cash
	(3)		cortex i narmaceaticais, inc.	(4)	(5)	

INSTRUCTIONS: If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

TABLE II SECURITIES SOLD DURING THE PAST 3 MONTHS

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

Title of Committee Cold

	Name and	Address of Seller	Title of Securities Sold	Date of Sale	Securities Sold	Gross Proceeds
		-	-	-	-	-
REM	MARKS:	(1) Based on closing price	e, \$0.12 as of 05/17/2011	(4) 10,445,57	79 shares of common stoc	ks and 4,081,633 shares

Data of Sala

(2) Shares as of 12/31/2010 as reported on Form 10-K

Name and Address of Caller

(5) The date of acquiring note

issuable upon exercise of warrant

Amount of

Grass Proposeds

Conveition Cold

Edgar Filing: CORTEX PHARMACEUTICALS INC/DE/ - Form 144

(3) Date of conversion from note

INSTRUCTIONS:

ATTENTION:

See the definition of person in paragraph (a) of Rule 144. Information is The person for whose account the securities to which this notice to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

05/18/2011

/s/ Dong Hoon Kim

DATE OF NOTICE

(SIGNATURE)

DATE OF PLAN ADOPTION OR GIVING OF INSTRUCTION,

IF RELYING ON RULE 10B5-1

The notice shall be signed by the person for whose account the securities are to be sold. At least one copy of the notice shall be manually signed. Any copies not manually signed shall bear typed or printed signatures.

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001) SEC 1147 (02-08)